{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,23]],"date-time":"2024-03-23T00:51:28Z","timestamp":1711155088920},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s00108-024-01674-7","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:15:05Z","timestamp":1709835305000},"page":"340-346","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prim\u00e4r bili\u00e4re Cholangitis\u00a0\u2013 Response-Kriterien der Erstlinientherapie und Perspektiven der Zweitlinientherapie","Primary biliary cholangitis\u2014response criteria of first-line treatment and perspectives of second-line therapy"],"prefix":"10.1007","volume":"65","author":[{"given":"Silja","family":"Steinmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"1674_CR1","doi-asserted-by":"publisher","first-page":"100188","DOI":"10.1016\/J.JTAUTO.2023.100188","volume":"6","author":"F Colapietro","year":"2023","unstructured":"Colapietro\u00a0F et\u00a0al (2023) PPAR agonists for the treatment of primary biliary cholangitis: old and new tales. J\u00a0Transl Autoimmun 6:100188. https:\/\/doi.org\/10.1016\/J.JTAUTO.2023.100188","journal-title":"J Transl Autoimmun"},{"issue":"23","key":"1674_CR2","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1056\/NEJMOA1714519\/SUPPL_FILE\/NEJMOA1714519_DISCLOSURES.PDF","volume":"378","author":"C Corpechot","year":"2018","unstructured":"Corpechot\u00a0C et\u00a0al (2018) A\u00a0placebo-controlled trial of bezafibrate in primary biliary cholangitis. N\u00a0Engl J Med 378(23):2171\u20132181. https:\/\/doi.org\/10.1056\/NEJMOA1714519\/SUPPL_FILE\/NEJMOA1714519_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"key":"1674_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000529","author":"C Corpechot","year":"2023","unstructured":"Corpechot\u00a0C et\u00a0al (2023) Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000529","journal-title":"Hepatology"},{"issue":"6","key":"1674_CR4","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/J.JHEP.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot\u00a0C et\u00a0al (2011) Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J\u00a0Hepatol 55(6):1361\u20131367. https:\/\/doi.org\/10.1016\/J.JHEP.2011.02.031","journal-title":"J Hepatol"},{"issue":"8","key":"1674_CR5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/GUTJNL-2019-319057","volume":"69","author":"MH Harms","year":"2020","unstructured":"Harms\u00a0MH et\u00a0al (2020) Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut 69(8):1502\u20131509. https:\/\/doi.org\/10.1136\/GUTJNL-2019-319057","journal-title":"Gut"},{"key":"1674_CR6","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/s0168-8278(23)00502-0","volume":"78","author":"V Hejda","year":"2023","unstructured":"Hejda\u00a0V et\u00a0al (2023) Results from a\u00a0planned interim analysis of a\u00a0randomized, double-blind, active-controlled trial evaluating the effects of obeticholic acid and bezafibrate on serum biomarkers in primary biliary cholangitis. J\u00a0Hepatol 78:S45. https:\/\/doi.org\/10.1016\/s0168-8278(23)00502-0","journal-title":"J Hepatol"},{"key":"1674_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.09.011","volume-title":"A\u00a0placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA","author":"GM Hirschfield","year":"2021","unstructured":"Hirschfield\u00a0GM et\u00a0al (2021) A\u00a0placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA https:\/\/doi.org\/10.1016\/j.jhep.2020.09.011"},{"issue":"1","key":"1674_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/J.JHEP.2017.03.022","volume":"67","author":"GM Hirschfield","year":"2017","unstructured":"Hirschfield\u00a0GM et\u00a0al (2017) EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J\u00a0Hepatol 67(1):145\u2013172. https:\/\/doi.org\/10.1016\/J.JHEP.2017.03.022","journal-title":"J Hepatol"},{"key":"1674_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/gutjnl-2017-315259","volume":"0","author":"GM Hirschfield","year":"2018","unstructured":"Hirschfield\u00a0GM et\u00a0al (2018) The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 0:1\u201327. https:\/\/doi.org\/10.1136\/gutjnl-2017-315259","journal-title":"Gut"},{"key":"1674_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306185","volume-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","author":"KV Kowdley","year":"2023","unstructured":"Kowdley\u00a0KV et\u00a0al (2023) Efficacy and safety of elafibranor in primary biliary cholangitis https:\/\/doi.org\/10.1056\/NEJMoa2306185"},{"issue":"4","key":"1674_CR11","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/HEP.32117","volume":"75","author":"KD Lindor","year":"2022","unstructured":"Lindor\u00a0KD et\u00a0al (2022) Primary biliary cholangitis: 2021 practice guidance update from the American Association for the study of liver diseases. Hepatology 75(4):1012\u20131013. https:\/\/doi.org\/10.1002\/HEP.32117","journal-title":"Hepatology"},{"issue":"1","key":"1674_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/HEP.26365","volume":"58","author":"GF Mells","year":"2013","unstructured":"Mells\u00a0GF et\u00a0al (2013) Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology 58(1):273\u2013283. https:\/\/doi.org\/10.1002\/HEP.26365","journal-title":"Hepatology"},{"issue":"7","key":"1674_CR13","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.14309\/AJG.0000000000000557","volume":"115","author":"CF Murillo Perez","year":"2020","unstructured":"Murillo Perez\u00a0CF et\u00a0al (2020) Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase. Am J Gastroenterol 115(7):1066\u20131074. https:\/\/doi.org\/10.14309\/AJG.0000000000000557","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"1674_CR14","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1053\/j.gastro.2022.08.054","volume":"163","author":"CF Murillo Perez","year":"2022","unstructured":"Murillo Perez\u00a0CF et\u00a0al (2022) Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a\u00a0clinical trial setting compared to real-world external controls. Gastroenterology 163(6):1630\u20131642.e3. https:\/\/doi.org\/10.1053\/j.gastro.2022.08.054","journal-title":"Gastroenterology"},{"issue":"7","key":"1674_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMOA1509840\/SUPPL_FILE\/NEJMOA1509840_DISCLOSURES.PDF","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens\u00a0F et\u00a0al (2016) A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N\u00a0Engl J Med 375(7):631\u2013643. https:\/\/doi.org\/10.1056\/NEJMOA1509840\/SUPPL_FILE\/NEJMOA1509840_DISCLOSURES.PDF","journal-title":"N Engl J Med"},{"issue":"3","key":"1674_CR16","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","volume":"113","author":"RE Poupon","year":"1997","unstructured":"Poupon\u00a0RE et\u00a0al (1997) Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 113(3):884\u2013890. https:\/\/doi.org\/10.1016\/S0016-5085(97)70183-5","journal-title":"Gastroenterology"},{"issue":"12","key":"1674_CR17","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.3748\/WJG.V29.I12.1795","volume":"29","author":"EI Rigopoulou","year":"2023","unstructured":"Rigopoulou\u00a0EI, Bogdanos\u00a0DP (2023) Role of autoantibodies in the clinical management of primary biliary cholangitis. World J Gastroenterol 29(12):1795. https:\/\/doi.org\/10.3748\/WJG.V29.I12.1795","journal-title":"World J Gastroenterol"},{"issue":"5","key":"1674_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1055\/A-1135-9306","volume":"58","author":"M Sebode","year":"2020","unstructured":"Sebode\u00a0M et\u00a0al (2020) Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. Z\u00a0Gastroenterol 58(5):431\u2013438. https:\/\/doi.org\/10.1055\/A-1135-9306","journal-title":"Z Gastroenterol"},{"issue":"10","key":"1674_CR19","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1111\/APT.16336","volume":"53","author":"PA Soret","year":"2021","unstructured":"Soret\u00a0PA et\u00a0al (2021) Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis. Aliment Pharmacol Ther 53(10):1138\u20131146. https:\/\/doi.org\/10.1111\/APT.16336","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"1674_CR20","doi-asserted-by":"publisher","first-page":"100898","DOI":"10.1016\/J.JHEPR.2023.100898","volume":"5","author":"S Steinmann","year":"2023","unstructured":"Steinmann\u00a0S et\u00a0al (2023) Accuracy of controlled attenuation parameter measurement for the detection of steatosis in autoimmune liver diseases. JHEP Reports 5(12):100898. https:\/\/doi.org\/10.1016\/J.JHEPR.2023.100898","journal-title":"JHEP Reports"},{"key":"1674_CR21","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1055\/s-0043-120199","volume":"55","author":"CP Strassburg","year":"2017","unstructured":"Strassburg\u00a0CP et\u00a0al (2017) S2k Leitlinie Autoimmune Lebererkrankungen Practice guideline autoimmune liver diseases. S2k Leitlinie Autoimmune. Z\u00a0Gastroenterol 55:1135\u20131226. https:\/\/doi.org\/10.1055\/s-0043-120199","journal-title":"Z Gastroenterol"},{"issue":"3","key":"1674_CR22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/J.JHEP.2021.04.010","volume":"75","author":"A Tanaka","year":"2021","unstructured":"Tanaka\u00a0A et\u00a0al (2021) Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J\u00a0Hepatol 75(3):565\u2013571. https:\/\/doi.org\/10.1016\/J.JHEP.2021.04.010","journal-title":"J Hepatol"},{"key":"1674_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/HC9.0000000000000179","volume":"7","author":"J Trivella","year":"2023","unstructured":"Trivella\u00a0J et\u00a0al (2023) Primary biliary cholangitis: epidemiology, prognosis, and treatment. Hepatol Commun 7:6. https:\/\/doi.org\/10.1097\/HC9.0000000000000179","journal-title":"Hepatol Commun"},{"issue":"1","key":"1674_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S12072-021-10276-6","volume":"16","author":"H You","year":"2022","unstructured":"You\u00a0H et\u00a0al (2022) APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis. Hepatol Int 16(1):1. https:\/\/doi.org\/10.1007\/S12072-021-10276-6","journal-title":"Hepatol Int"},{"issue":"1","key":"1674_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1002\/HEP.26322","volume":"58","author":"LN Zhang","year":"2013","unstructured":"Zhang\u00a0LN et\u00a0al (2013) Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a\u00a014-year cohort study. Hepatology 58(1):264\u2013272. https:\/\/doi.org\/10.1002\/HEP.26322","journal-title":"Hepatology"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01674-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-024-01674-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-024-01674-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T11:04:06Z","timestamp":1711105446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-024-01674-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1674"],"URL":"https:\/\/doi.org\/10.1007\/s00108-024-01674-7","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"1 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Steinmann und C.\u00a0Schramm geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}